Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2018

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
X-Linked Adrenoleukodystrophy
Interventions
DRUG

Sobetirome (NV1205)

Once a day oral dose of the study drug

Trial Locations (13)

3168

Monash Health, Clayton

Unknown

Hospital Austral, Buenos Aires

Hospital General de ninos Pedro de Elizalde, Buenos Aires

Hospital Clínico San Borja Arriarán, Santiago

Hospital Dr. Luis Calvo Mackenna, Santiago

Fundacion Cardioinfantil, Bogotá

Hôpital Bicêtre - Paris Sud, Paris

Endocrinology Research Center, Moscow

Moscow Morozov's Children Clinical Hospital, Moscow

Saint Petersburg State Pediatric Medical University, Saint Petersburg

National Children's Specialized Hospital 'OKHMATDET', Kiev

Great Ormond Street Hospital for Children, London

Manchester Children's Hospital, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

NeuroVia, Inc.

INDUSTRY